Diabetic Neuropathy News and Research

RSS
Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.
Diabetes plays a vital role in regulating brain cholesterol: Research

Diabetes plays a vital role in regulating brain cholesterol: Research

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

CD31 positive cells have potential for treating peripheral artery disease: Research

CD31 positive cells have potential for treating peripheral artery disease: Research

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

California companies are developing new medicines for diabetes: Report

California companies are developing new medicines for diabetes: Report

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

New circular external fixator device for diabetic Charcot foot treatment

New circular external fixator device for diabetic Charcot foot treatment

Circular external fixator enables over 90% of Charcot foot patients to walk normally again

Circular external fixator enables over 90% of Charcot foot patients to walk normally again

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

New Infrared Relief therapy now available for patients with diabetic neuropathies

New Infrared Relief therapy now available for patients with diabetic neuropathies

Paralysis from a stroke: Rare nerve transfer improves mobility

Paralysis from a stroke: Rare nerve transfer improves mobility

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

TENS therapy is not effective against chronic low-back pain

TENS therapy is not effective against chronic low-back pain

Second successful phrenic nerve decompression surgery

Second successful phrenic nerve decompression surgery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.